Over the last couple of years I have been writing blogs suggesting that we adopt a Most-Favored Nation clause in regard to pharmaceuticals.
It appears that President Trump has adopted this concept and has incorporated it in some of his Executive Orders. However, for this concept to be effective and to be a long term solution, Congress needs to adopt it as part of a statute, not just applicable to Medicare or other governmental programs, but applicable to all pharmaceuticals in interstate commerce.
It does not appear that this will occur in this Session of Congress, but hopefully it will be addressed in the next Administration, whether Trump or Biden, as well as the next Congress.